Wehi-539 and its successors, A-1155463 and A-1331852, are targeting BCLX within sub-nanomolar-range [26] but cause thrombocytopenia, limiting clinical application [27, 28]. This evidence concerns the gene BCL2L1 and Thrombocytopenia.